Macular Translocation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Macular translocation is a complex vitreoretinal surgical procedure in which the fovea — the central retina responsible for high-acuity and colour vision — is physically relocated from its anatomical position overlying diseased retinal pigment epithelium (RPE) or a subfoveal choroidal neovascular membrane (CNV) to a healthier area of RPE and Bruch's membrane. Developed primarily in the late 1990s and early 2000s as a surgical approach to neovascular (wet) age-related macular degeneration (AMD) and other causes of subfoveal CNV, macular translocation represented a conceptually bold attempt at functional rescue when no effective pharmacological treatments existed.

Two principal techniques were developed: limited macular translocation (LMT), which achieves small foveal displacement by partial scleral imbrication or retinotomy at the periphery; and full 360-degree macular translocation (FMT), which involves complete retinal detachment, 360-degree peripheral retinotomy, and repositioning of the entire neurosensory retina — enabling larger foveal displacement but at the cost of significant ocular cyclotorsion, requiring second-stage extraocular muscle surgery to correct torsional diplopia.

The clinical landscape for macular translocation was fundamentally transformed by the introduction of intravitreal anti-VEGF (vascular endothelial growth factor) pharmacotherapy. The approval of ranibizumab in 2006 (ANCHOR and MARINA trials) established anti-VEGF injection as superior to photodynamic therapy and surgical approaches for most forms of neovascular AMD. Macular translocation is now a largely historical procedure in high-income settings with access to modern pharmacotherapy, though it retains relevance for specific recalcitrant CNV subtypes and continues to inform ongoing subretinal surgical approaches.

1. Neovascular (Wet) Age-Related Macular Degeneration (nAMD / Wet AMD):

AMD is the leading cause of irreversible legal blindness in individuals aged >50 years in high-income countries. Neovascular AMD (approximately 10–15% of all AMD) is characterised by pathological ingrowth of choroidal new vessels (choroidal neovascularisation, CNV) through Bruch's membrane into the subretinal space or sub-RPE space, with resultant fluid accumulation, haemorrhage, and rapid photoreceptor loss. Without treatment, vision loss from subfoveal CNV can progress from normal to severe impairment (BCVA <6/60) within 12–24 months.

The CNV is classified by fluorescein angiography as: classic CNV (well-demarcated, early leakage — 25–30% of cases, most visually threatening); occult CNV (fibrovascular RPE detachment or late leakage — 60–70%, slower progression); and predominantly classic CNV (>50% classic component). Optical coherence tomography (OCT) has superseded fluorescein angiography for treatment decisions, with OCT-A enabling CNV flow mapping without dye injection.

2. Other Causes of Subfoveal CNV:

Macular translocation was also applied (in smaller case series) to subfoveal CNV secondary to pathological myopia (myopic CNV — accounts for 8% of legal blindness in high-income countries; treated with single anti-VEGF injection in most cases), angioid streaks (Bruch's membrane cracks in pseudoxanthoma elasticum, sickle cell disease), and ocular histoplasmosis syndrome (OHS) — though anti-VEGF has now supplanted surgery for these indications as well.

3. RPE65-Associated Retinal Dystrophies (Gene Therapy Context):

A separate retinal disease category where modern surgical delivery techniques derived from macular surgery research have proven transformative: Leber congenital amaurosis type 2 (LCA2) and RPE65-associated retinitis pigmentosa are caused by biallelic mutations in the RPE65 gene encoding retinal pigment epithelium 65 (RPE65, essential for the visual cycle). Voretigene neparvovec (Luxturna), an AAV2-RPE65 gene therapy, is delivered subretinally via surgical injection — directly demonstrating the continued importance of precision retinal surgical techniques.

Historical Selection Criteria for Macular Translocation (pre-anti-VEGF era):

In the era when macular translocation was actively performed (approximately 1998–2008), patient selection criteria for FMT included:

• Subfoveal CNV (classic, minimally classic, or occult) secondary to AMD with documented rapid progression
• Best-corrected visual acuity (BCVA) of 6/24 to 6/120 (moderate to severe vision loss — sufficient residual photoreceptor function to benefit from foveal relocation)
• Extrafoveal healthy RPE of adequate extent to receive the translocated fovea (assessed by indocyanine green angiography — ICG)
• Fellow eye BCVA ≥6/12 (contraindication: fellow eye already severely affected — surgical risk unacceptable for the only remaining functional eye)
• Patient willingness and fitness for prolonged surgery (2–4 hours under general anaesthesia) and mandatory second-stage strabismus surgery

LMT vs FMT Selection:

LMT was preferred for smaller CNV lesions requiring only limited foveal displacement (typically ≤1 disc diameter), avoiding the cyclotorsion complication of FMT. FMT was reserved for larger CNV lesions requiring more substantial foveal relocation but offered the advantage of not being constrained by CNV size. LMT achieved translocation distances of 200–800 µm; FMT enabled translocation of up to 3,000 µm.

Current Indications (2026):

Macular translocation is now performed only in rare, selected scenarios:

• Recalcitrant neovascular AMD unresponsive to multiple classes of anti-VEGF therapy (ranibizumab, aflibercept, brolucizumab) and photodynamic therapy combination approaches — where the subfoveal RPE is irreversibly destroyed but adjacent healthy RPE remains viable.
• Large submacular haemorrhages with preserved photoreceptor potential where displacement of blood off the fovea (via pneumatic displacement or subretinal tissue plasminogen activator) is insufficient.
• Investigational use in clinical trial settings exploring surgical delivery platforms for subretinal therapeutics.
• Resource-limited settings where anti-VEGF therapy is inaccessible or prohibitively expensive — though training for FMT is now rare globally.

Limited Macular Translocation (LMT):

LMT achieves foveal displacement without complete retinal detachment. Techniques include: (1) Scleral imbrication (Aisenbrey/Eckardt technique) — partial-thickness scleral flaps are created and sutured to shorten the sclera inferiorly, causing a controlled inferior retinal fold that displaces the fovea superiorly away from the CNV. The amount of translocation is limited to approximately 800–1,000 µm. (2) Eccentric peripheral retinotomy — a limited retinotomy remote from the macula allows controlled retinal sliding. LMT procedures take approximately 45–90 minutes under general anaesthesia and do not cause clinically significant cyclotorsion in most cases. CNV excision or photodynamic therapy to the now-extrafoveal CNV completes the procedure. Visual results in published series showed improvement in approximately 30–40% of patients, stabilisation in 30–40%, and deterioration in 20–30%.

Full 360-Degree Macular Translocation (FMT):

FMT is a technically complex procedure that proceeds in stages:

1. Standard pars plana vitrectomy (three-port, 20- or 23-gauge) with complete vitreous removal and creation of posterior vitreous detachment.
2. Subretinal injection of balanced salt solution (BSS) or viscoelastic to detach the entire neurosensory retina from the RPE, creating a bullous rhegmatogenous-type retinal detachment.
3. 360-degree peripheral retinotomy (cutting the retina circumferentially at the ora serrata or periphery) — this releases the retina to rotate freely.
4. Controlled rotation of the entire retina by 30–60 degrees around the optic disc axis using internal retinal manipulation — displacing the fovea to a predetermined healthy RPE target zone (confirmed by ICG angiography landmarks).
5. Fluid-air exchange followed by perfluorocarbon liquid (PFCL) to flatten the rotated retina. Laser retinopexy (360-degree endolaser) to the peripheral retinotomy edge secures the retina. Silicone oil or long-acting gas (C3F8) tamponade to maintain position.
6. If CNV excision is planned: subretinal instrumentation to grasp and remove the fibrovascular membrane through a small retinotomy.

FMT — Cyclotorsion and Strabismus Surgery:

The Achilles heel of FMT is cyclotorsion: rotating the entire retina by 30–60 degrees creates an equivalent cyclotorsion of the entire ocular image, causing incapacitating torsional diplopia and disorientation when binocular vision is attempted. This requires a mandatory second surgical procedure — counter-rotation of the extraocular muscles — typically performed 4–8 weeks after retinal surgery once the oil/gas is removed and the eye has stabilised. Extraocular muscle surgery involves detaching and repositioning the superior and inferior oblique or rectus muscles to rotate the eye in the opposing direction, neutralising the retinal torsion. Only surgeons with combined vitreoretinal and strabismus expertise can perform FMT. Published series report successful torsion correction in 60–80% of patients, but residual diplopia requiring prism correction persists in a significant minority.

Modern Standard: Intravitreal Anti-VEGF Therapy

Anti-VEGF agents have entirely supplanted macular translocation as first-line therapy for neovascular AMD. The pivotal trials established: ANCHOR trial (ranibizumab 0.5 mg vs photodynamic therapy in predominantly classic CNV — 96% of ranibizumab patients lost <15 letters vs 64% PDT; 40% gained ≥15 letters vs 6% PDT); MARINA trial (ranibizumab vs sham in minimally classic/occult CNV — 95% vs 62% avoiding severe vision loss). Current agents include: ranibizumab (Lucentis, 0.5 mg q4w), bevacizumab (Avastin, 1.25 mg — off-label, CATT trial: equivalent efficacy to ranibizumab), aflibercept (Eylea, 2 mg q4w × 3 then q8w — VIEW 1/2 trials: non-inferior to ranibizumab), brolucizumab (Beovu, 6 mg q12w after loading — HAWK/HARRIER trials: non-inferior with fewer injections but risk of retinal vasculitis), and faricimab (Vabysmo, dual VEGF-A/Ang-2 blockade — TENAYA/LUCERNE trials: up to q16w dosing intervals, reducing injection burden).

Subretinal Drug Delivery:

Surgical expertise from macular translocation has informed emerging subretinal therapeutic delivery platforms. The LEAPH study and commercial delivery systems (e.g., Orbit SRS — Gyroscope Therapeutics) enable precise subretinal injection of gene therapies and cell-based therapies, targeting the RPE layer directly. This has enabled: voretigene neparvovec (Luxturna) for RPE65-associated dystrophies (FDA-approved 2017) — delivered via subretinal injection in the surgical suite; and GT005 (C3 inhibitor for geographic atrophy — FOCUS trial; Gyroscope) delivered subretinally under direct surgical visualisation.

Published outcomes for macular translocation must be interpreted in their historical context — pre-anti-VEGF era, when no effective alternative existed:

• FMT — Published series (Eckardt et al., de Juan et al.): In patients with predominantly classic subfoveal CNV, FMT achieved vision improvement (≥2 lines) in approximately 25–40% and stabilisation in 40–50%. The Freiburg group reported mean visual acuity improvement of +2.8 letters (vs −14 in natural history) with FMT in classic CNV. However, these results were achieved at substantial surgical risk and required second-stage strabismus surgery.
• LMT outcomes: Somewhat inferior vision gain to FMT (constrained by smaller translocation distance), but with significantly lower complication rates and without cyclotorsion. Visual improvement in 20–35%, stabilisation in 35–45%.
• Comparison with PDT (pre-anti-VEGF comparative data): The German TINeR study compared FMT with PDT for predominantly classic CNV: FMT showed superiority in visual acuity outcomes but at the cost of higher serious adverse event rates.
• Subretinal CNV excision as adjunct: Excision of the CNV membrane at the time of FMT aims to remove the stimulus for recurrent neovascularisation. However, associated RPE damage at the excision site limits outcomes; recurrence rates of 30–40% within 2 years were reported even with excision.
• Modern context: Anti-VEGF therapy achieves mean visual acuity gains of +8–10 letters over 2 years in neovascular AMD, with 30–40% of patients gaining ≥15 letters (3 lines) — outcomes substantially superior to historical macular translocation series, without the surgical risk of intraoperative retinal detachment or cyclotorsion.

Macular translocation carries a substantially higher risk profile than intravitreal injection or photodynamic therapy, reflecting its invasive intraocular nature:

Intraoperative complications:

• Iatrogenic retinal breaks and retinal detachment during detachment creation or retinotomy
• Subretinal haemorrhage during CNV excision
• Inadvertent foveal damage during membrane extraction
• Choroidal haemorrhage (expulsive or limited)

Early post-operative complications:

• Proliferative vitreoretinopathy (PVR): The most feared complication, occurring in 5–15% after FMT. Epiretinal membrane contraction causes retinal re-detachment and may result in permanent severe vision loss. Requires re-vitrectomy with membrane peeling.
• Rhegmatogenous retinal detachment: 10–20% incidence after FMT (higher than standard vitrectomy due to 360-degree retinotomy).
• Subretinal fluid persistence: Incomplete reattachment at the translocation site.
• CNV recurrence: 30–40% within 2 years at or adjacent to the new foveal position; may require additional treatment (anti-VEGF or PDT).

FMT-specific complications:

• Cyclotorsion and torsional diplopia: Universal after FMT requiring strabismus surgery; persistent torsional diplopia occurs in 15–25% despite corrective surgery.
• Strabismus surgery complications: Overcorrection or undercorrection requiring revision; diplopia in primary gaze; restriction of ocular motility.
• Silicone oil complications: Secondary glaucoma, cataract, and emulsification requiring oil removal surgery (typically at 3 months).

Late complications:

• Epiretinal membrane formation at the new foveal position
• Macular pucker
• Geographic atrophy progression at the translocation site
• Progressive photoreceptor loss from persistent subretinal fluid or RPE atrophy

The overall serious adverse event rate for FMT in published series is 15–30%, significantly higher than the <0.1% serious adverse event rate (endophthalmitis, retinal detachment) for monthly intravitreal injections in contemporary AMD management.

Post-operative follow-up after macular translocation requires intensive ophthalmological surveillance:

Immediate post-operative period (0–4 weeks):

• Strict head positioning for gas tamponade (face-down position for 1–2 weeks if C3F8 gas used; position dependent on rotation direction).
• Daily or every-other-day intraocular pressure monitoring (silicone oil-related hypertension requires topical IOP-lowering therapy or valve implantation).
• Fundal examination and OCT at 1 week to confirm retinal position and assess the translocation site.
• Steroid and antibiotic topical therapy for 4–6 weeks.

Short-to-medium term (1–6 months):

• Assessment of cyclotorsion (Maddox rod testing, Hess chart) and planning of strabismus surgery — typically performed at 4–8 weeks post-vitrectomy.
• Silicone oil removal procedure (typically at 3 months) — conducted under general anaesthesia as a separate surgical episode.
• Visual acuity and contrast sensitivity assessment at 3, 6, and 12 months.
• OCT and fundus photography to assess RPE integrity at the new foveal position and monitor for CNV recurrence.
• Fluorescein or OCT-A angiography at 3 months and 12 months to detect recurrent CNV.

Long-term surveillance:

• Annual ophthalmological review with OCT and visual acuity; fluorescein angiography or OCT-A if CNV recurrence is suspected.
• Fellow eye monitoring: all AMD patients have significant risk of neovascular conversion in the fellow eye — Amsler grid daily self-monitoring and prompt reporting of new metamorphopsia or central scotoma.
• AMD risk modification: smoking cessation (strongest modifiable risk factor — doubles AMD progression risk); AREDS2 supplements (lutein/zeaxanthin + vitamins C/E + zinc) for intermediate AMD or fellow-eye AMD; management of cardiovascular risk factors.

Macular translocation surgery was always substantially more expensive than alternative treatments due to its technical complexity, requirement for extended operating time under general anaesthesia, specialist equipment (25-gauge vitrectomy system, perfluorocarbon liquids, endolaser), silicone oil, and mandatory second-stage strabismus surgery. In contemporary practice, cost is rarely a relevant consideration because the procedure is almost never performed as first-line treatment.

The dominant cost consideration in neovascular AMD management is now intravitreal anti-VEGF therapy:

• Ranibizumab (Lucentis): ~USD 1,900–2,000 per injection in the USA; ~£550–650 per injection in the UK (NHS tariff). Annual cost: USD 20,000–24,000 if monthly (treat-and-extend protocols reduce to USD 10,000–14,000/year).
• Bevacizumab (Avastin, off-label compounded): ~USD 50–60 per injection — approximately 40× cheaper than ranibizumab with equivalent clinical efficacy (CATT, IVAN, GEFAL trials). Widely used in global ophthalmology where cost is a barrier.
• Aflibercept (Eylea): ~USD 1,800 per injection; q8w after loading phase reduces annual injection frequency and cost. Biosimilar aflibercept (Yesafili, Opuviz, Aybintio) approved in USA/Europe 2023 at 30–40% discount.
• Faricimab (Vabysmo): ~USD 2,000 per injection; q12–16w intervals in responders may reduce annual cost to USD 8,000–10,000.

For resource-limited settings where anti-VEGF access is restricted, the historical rationale for macular translocation as a one-time surgical intervention with potential long-term benefit — versus indefinite monthly injections — held some economic logic. However, training capacity for FMT has virtually disappeared globally, making this theoretical advantage impractical. Bevacizumab remains the most cost-effective anti-VEGF strategy for AMD in low- and middle-income countries (WHO essential medicines list consideration).

The remarkable pharmacological and biological advances since the early 2000s have rendered macular translocation obsolete for the vast majority of patients with neovascular AMD or subfoveal CNV. Current and emerging alternatives include:

1. Intravitreal Anti-VEGF Therapy (Current Standard of Care):

Monthly or treat-and-extend (T&E) intravitreal injections are the first-line treatment for neovascular AMD globally. The PORT DELIVERY SYSTEM (PDS) with ranibizumab (Susvimo) — an ocular implant refilled every 24 weeks — reduces injection frequency substantially (ARCHWAY trial). High-dose aflibercept 8 mg (Eylea HD) achieves q12–16w dosing intervals in the PULSAR trial, further reducing injection burden.

2. Photodynamic Therapy (PDT) — Verteporfin:

Photodynamic therapy with verteporfin (Visudyne) photosensitiser, once the standard of care (TAP/VIP trials), is now used primarily as adjunctive therapy in combination with anti-VEGF for polypoidal choroidal vasculopathy (PCV) — a CNV subtype prevalent in Asian populations (30–50% of neovascular AMD in Asia). PDT + anti-VEGF (EVEREST-II trial) achieves higher polyp regression rates than anti-VEGF alone.

3. Gene Therapy for AMD — RGX-314 and GT005:

• RGX-314 (RegenxBio): AAV8 vector carrying the ranibizumab-coding sequence, delivered subretinally or suprachoroidally to enable in-situ anti-VEGF production by retinal cells — converting the eye into a biological anti-VEGF factory. Phase IIb/III ATMOSPHERE and ASCENT trials ongoing. One injection may provide continuous anti-VEGF expression for years, potentially eliminating the need for repeated injections.
• GT005 (Gyroscope Therapeutics/Novartis): AAV2 vector delivering complement factor I (CFI) gene to the RPE, addressing the complement pathway dysregulation driving geographic atrophy progression. Delivered subretinally under direct surgical vision. FOCUS trial (phase II) underway.
• ADVM-022 (Adverum Biotechnologies): Intravitreal AAV2.7m8 vector expressing aflibercept cDNA — a simpler delivery without subretinal surgery requirement. Phase I OPTIC trial demonstrates sustained aflibercept expression.

4. Cell-Based Therapies — RPE Transplantation and Stem Cells:

• OPRegen (Lineage Cell Therapeutics / Roche): Embryonic stem cell-derived RPE cells (OpRegen) delivered subretinally via surgical injection under the neuroretina in geographic atrophy. Phase I/IIa CEDAR/SEQUOIA trials demonstrate safety and evidence of RPE engraftment; some treated eyes show stabilisation of RPE and photoreceptor layer thickness.
• CPCB-RPE1 (California Project to Cure Blindness): RPE monolayer on a polyester scaffold, surgically implanted subretinally as a complete RPE sheet. Proof-of-concept data in advanced AMD.
• iPSC-derived RPE: Patient-specific induced pluripotent stem cell-derived RPE cells under investigation in Japan (RIKEN) and globally — eliminates immunological rejection risk.

5. Sustained-Release Drug Delivery:

The Port Delivery System (PDS, Susvimo) is a refillable intravitreal implant sutured into the pars plana, releasing ranibizumab continuously; refilled in-office every 24 weeks. Reduces injection visits and maintains consistent drug levels. Alternative: biodegradable intravitreal implants (OcuSense, EyeD Pharma) in development.

6. Voretigene Neparvovec (Luxturna) — RPE65 Gene Therapy:

For RPE65-associated retinal dystrophies (LCA2, RP due to RPE65 mutations), voretigene neparvovec is the first FDA-approved in-vivo gene therapy for a genetic disease (December 2017). Delivered by subretinal injection into each eye (sequential surgery) under general anaesthesia via a small retinotomy and bleb injection. Improves functional vision (multiluminance mobility testing) and retinal sensitivity in a majority of treated patients, with sustained benefit at 4 years in the phase III trial (Russell et al., Lancet 2017). This application, though targeting a different disease, represents the most clinically mature application of subretinal surgical delivery — a technique with direct conceptual heritage from macular translocation research.